ScholarIQanswers from OpenAlex & ORCID
Hussein A. Tawbi
ResearcherPublications, citations & collaboration network
Hussein A. Tawbi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hussein A. Tawbi have?
ScholarIQindexed works
Hussein A. Tawbi has 545 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hussein A. Tawbi have?
ScholarIQcitation count
Hussein A. Tawbi has 25,714 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hussein A. Tawbi?
ScholarIQh-index
Hussein A. Tawbi has an h-index of 63 in OpenAlex.
What is the i10-index of Hussein A. Tawbi?
ScholarIQi10-index
Hussein A. Tawbi has an i10-index of 154 in OpenAlex.
What is the ORCID of Hussein A. Tawbi?
ScholarIQorcid
The ORCID for Hussein A. Tawbi is on the source record.
What is the OpenAlex record for Hussein A. Tawbi?
ScholarIQopenalex
The OpenAlex for Hussein A. Tawbi is on the source record.
What are the most-cited papers on Hussein A. Tawbi?
ScholarIQmost cited works
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, James Hu, Sandra P. D’Angelo, Steven Attia, Richard F. Riedel, Dennis A. Priebat, Sujana Movva, Lara E. Davis, Scott H. Okuno, Damon R. Reed, John Crowley, Lisa H. Butterfield, Ruth Salazar, Jaime Rodriguez‐Canales, Alexander J. Lazar, Ignacio I. Wistuba, Laurence H. Baker, Robert G. Maki, Denise K. Reinke, Shreyaskumar Patel
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri, Margaret von Mehren, Robin L. Jones, Martee L. Hensley, Scott M. Schuetze, Arthur P. Staddon, Mohammed Milhem, A. Elias, Kristen N. Ganjoo, Hussein A. Tawbi, Brian Andrew Van Tine, Alexander I. Spira, Andrew Dean, Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, Trilok Parekh, Robert G. Maki, Shreyaskumar Patel
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria, Sangeetha M. Reddy, Hussein A. Tawbi, Michael A. Davies, Merrick I. Ross, Isabella C. Glitza, Janice N. Cormier, Carol M. Lewis, Wen-Jen Hwu, Ehab Hanna, Adi Diab, Michael K. Wong, Richard E. Royal, Neil D. Gross, Randal S. Weber, Stephen Y. Lai, Richard A. Ehlers, Jorge Blando, Denái R. Milton, Scott E. Woodman, Robin Kageyama, Daniel K. Wells, Patrick Hwu, Sapna P. Patel, Anthony Lucci, Amy C. Hessel, Jeffrey E. Lee, Jeffrey E. Gershenwald, Lauren Simpson, Elizabeth M. Burton, Liberty Posada, Lauren E. Haydu, Linghua Wang, Shaojun Zhang, Alexander J. Lazar, Courtney W. Hudgens, Vancheswaran Gopalakrishnan, Alexandre Reuben, Miles C. Andrews, Christine N. Spencer, Víctor G. Prieto, Padmanee Sharma, James P. Allison, Michael T. Tetzlaff, Jennifer A. Wargo
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
Ulrich Keilholz, P.A. Ascierto, Reinhard Dummer, Caroline Robert, Paul Lorigan, Alexander C. J. van Akkooi, Ana Arance, Christian U. Blank, V. Chiarion Sileni, Marco Donia, Mark B. Faries, Caroline Gaudy‐Marqueste, Helen Gogas, Jean‐Jacques Grob, Matthias Gückenberger, John B.A.G. Haanen, Andrew Hayes, Christoph Höeller, Célèste Lebbé, Iwona Ługowska, Mario Mandalà, Iván Márquez‐Rodas, Paul Nathan, Bart Neyns, Roger Olofsson Bagge, Susana Puig, Piotr Rutkowski, Bastian Schilling, Vernon K. Sondak, Hussein A. Tawbi, Alessandro Testori, Olivier Michielin